**

Clinical SpecialityUrology imaging

PROSTATE APPLICATIONS

▶ Instant comprehensive lesion assessment

■ PI-RADS steering committee of the American College of Radiology (ACR) emphasizes the role of diff usion and T2-weighted imaging for prostate lesion assessment.

Olea Sphere® dedicated applications include advanced diff usion, qualitative & quantitative perfusion parameters, and off er eff icient simultaneous multiparametric analysis of all available sequences, with prostate specifi c display. Olea Sphere® prostate applications also include PI-RADS v1.0 or v2.0 standardized report.

▶ High-quality diff usion assessment

IVIM mapsADC map

PROSTATE APPLICATIONS**

▶ PI-RADS v2.0 in Olea Sphere® Prostate applications

▶ “Dominant sequence” concept (depends on the location of the lesion)

In order to further improve the detection, characterization and staging of prostate cancers, Olea Medical® updated the dedicated report for prostate applications in accordance with the PI-RADS v2.0. This revised version was diligently developed by the PI-RADS steering committee of the American College of Radiology (ACR) and the ESUR prostate MRI working group, through enriched lexicon, to standardize acquisition and interpretation.Radiologists now have the choice between PI-RADS v1.0 or v2.0 according to their practice.

■ PI-RADS v2.0 scoring report

▶ Simplifi ed PI-RADS v2.0 assessment score

Localization of the lesion ▶ Dominant sequencePeripheral zone ▶ Di� usion-weighted MRITransition zone ▶ T2-weighted MRI

Probability of clinically signi� cant cancer:Very low ▶ 1Low ▶ 2Intermediate ▶ 3High ▶ 4Very high ▶ 5

Olea Medical®- ZI Athelia IV - 93, avenue des Sorbiers - 13600 La Ciotat - FRANCEPH +33 4 42 71 24 20 - FX +33 4 42 71 24 27 - contact@olea-medical.com

www.olea-medical.com

▶ Facilitated communication of results between physicians

Meaningful reporting including

lesion locationand volumes

▶ Tested & trusted solution■ Multiparametric analysis“Multi-parameter display of all available sequences is essential. Not moving from one software packageto another to use perfusion or di� usion makes a lot of sense. Clearly we need all sequences to be available and simultaneously displayed on the screen.”

■ IVIM: advanced diff usion plug-in“Olea Sphere® main impact is di� usion with the IVIM module. This is the � rst time that I can use di� usionfunctions on a workstation to calculate the bi-exponential curve of the di� usion. With this plug-in, we can analyze early di� usion with very small b. The longest b (calculated b, b2000, b3000 and above) aregoing to be essential tools for di� icult cases, to di� erentiate between cancers and in� ammatory tissuesor adenoma nodules.”François Cornud, MD, Cochin Hospital, Paris, France

■ Nougaret S, Vargas HA, Lakh-man Y, Sudre R, Do RK, Bibeau F, Azria D, Assenat E, Molinari N, Pierredon MA, Rouanet P, Guiu B. Intravoxel Incoherent Motion-de-rived Histogram Metrics for As-sessment of Response after Combined Chemotherapy and Ra-

diation Therapy in Rectal Cancer: Initial Experience and Comparison bet-ween Single-Section and Volu-metric Analyses. Radiology.2016 Feb 26:150702.

■ Cornud F, Brolis L, Delong-champs NB, Portalez D, Mala-vaud B, Renard-Penna R, Mozer P. TRUS-MRI image registration : a paradigm shift in the diagnosis of signifi cant prostate cancer. Ab-dom Imaging. 2013 Dwec;38(6):1447-63.

▶ References

*Olea Sphere® v3.0, medical imaging post-processing software, is a medical device manufactured and marketed by Olea Medical®. This medical device is reserved for health professionals. This software program has been designed and manufactured according to the EN ISO 13485 quality management system. Read the instructions in the notice carefully before any use. Instructions for Use are available on http://www.olea-medical.com/en/ Manufacturer: Olea Medical® (France). Medical devices Class IIa / Notifi ed body: CE 0459 LNE-GMED.OM-MK-OLEASPHERE-30-028-PRO-V03-EN